<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article41</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/ENGAGE_AF-TIMI_48" style="display:block; margin-bottom:10px;">ENGAGE AF-TIMI 48 Original</a></li>
<h2><strong>ENGAGE AF-TIMI 48</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Edoxaban versus Warfarin in Patients with Atrial Fibrillation". The New England Journal of Medicine. 2013. 369:2093-2104. PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcomes<br/>
8.2 Secondary Outcome<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with moderate-to-high-risk atrial fibrillation, is edoxaban noninferior or superior to warfarin for the prevention of stroke or systemic embolism?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with moderate-to-high-risk atrial fibrillation, both high-dose and low-dose regimens of edoxaban were noninferior to warfarin for prevention of stroke or systemic embolism, with significantly lower rates of bleeding and death from cardiovascular causes.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
Edoxaban, an oral direct factor Xa inhibitor, showed noninferiority to warfarin in preventing stroke or systemic embolism among atrial fibrillation patients. High-dose edoxaban showed a trend toward superior efficacy compared to warfarin, while low-dose edoxaban was associated with less bleeding risk.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the latest knowledge cut-off, this trial may influence guidelines by providing a new oral anticoagulant option for the management of stroke prevention in atrial fibrillation, especially for patients who have a moderate-to-high risk of stroke.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, double-dummy, randomized controlled trial<br/>
- N=21,105<br/>
- Warfarin (n=7,031), High-dose edoxaban (n=7,036), Low-dose edoxaban (n=7,038)<br/>
- Setting: 1393 centers in 46 countries<br/>
- Enrollment: 2008-2010<br/>
- Mean follow-up: 2.8 years<br/>
- Analysis: Intention-to-treat<br/>
- Primary outcome: Stroke or systemic embolism<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria<br/>
- Age ≥ 21 years<br/>
- Atrial fibrillation documented within 12 months before randomization<br/>
- CHADS2 score of 2 or higher<br/>
- Anticoagulation therapy planned for duration of the trial<br/>
<br/>
Exclusion Criteria<br/>
- Atrial fibrillation due to a reversible disorder<br/>
- Estimated creatinine clearance &lt; 30 ml per minute<br/>
- High risk of bleeding<br/>
- Use of dual antiplatelet therapy or other anticoagulation therapy<br/>
- Mitral stenosis or other indications requiring anticoagulation therapy<br/>
- Recent acute coronary syndromes, stroke, or inability to adhere to study procedures<br/>
<br/>
Baseline Characteristics<br/>
- Demographics and clinical characteristics were well balanced among the three groups.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Patients were randomized to receive either warfarin (INR 2.0-3.0), high-dose edoxaban (60 mg), or low-dose edoxaban (30 mg).<br/>
- Dose was halved for patients with creatinine clearance of 30-50 ml per minute, body weight ≤ 60 kg, or concomitant use of potent P-glycoprotein inhibitors.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes<br/>
- High-dose edoxaban showed noninferiority (and trend toward superiority) compared to warfarin (annualized rate 1.18% vs. 1.50%).<br/>
- Low-dose edoxaban was noninferior to warfarin (annualized rate 1.61% vs. 1.50%).<br/>
<br/>
Secondary Outcome<br/>
- Major bleeding rates were lower with high-dose edoxaban (2.75%) and low-dose edoxaban (1.61%) compared to warfarin (3.43%).<br/>
- Death rates from cardiovascular causes were lower with both doses of edoxaban than with warfarin.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- No specific antidote for edoxaban is available.<br/>
- Direct comparative studies are needed to determine real clinical differences compared to other new anticoagulants.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- Supported by Daiichi Sankyo Pharma Development.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- Full text of the original article in The New England Journal of Medicine.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
